Across the 12 week placebo controlled Phase III clinical studies, mean haemoglobin concentrations decreased for patients in the Volibris groups and were detected as early as week 4 (decrease by 0.83 g/ dl); mean changes from baseline appeared to stabilise over the subsequent 8 weeks.
12- nädalastes platseebokontrollitud III faasi kliinilistes uuringutes vähenes Volibris' t saanud patsientidel keskmine hemoglobiinisisaldus, mis avastati juba 4. nädalal (langus 0, 83 g/ dl); keskmised muutused algväärtusest stabiliseerusid järgneva 8 nädala jooksul.